Melanoma Matters

Melanoma Matters Pod
  • 5.0 (2)
  • MEDICINE
  • UPDATED WEEKLY
Melanoma Matters

From the UK to the USA - Melanoma Matters is on a mission! Hosts James Larkin and Sapna Patel are spreading the word on melanoma, one podcast at a time. Tune in for a critical review of the literature and a discussion of how we incorporate the data into our practices...across the pond(s). #MelanomaMatters video podcast

  1. APR 7

    Ep 67: SITC white paper on ICI resistance

    Summary In this conversation, James Larkin and Sapna Patel discuss the consensus definitions for resistance to immune checkpoint inhibitors, focusing on a recent paper from the Journal of Immunotherapy of Cancer. They explore the complexities of primary and secondary resistance, the importance of defining these terms for clinical trials, and the challenges in trial design and control arms. The discussion emphasizes the need for clear definitions to improve patient outcomes and guide future research in oncology. Keywords immune checkpoint inhibitors, cancer treatment, resistance, clinical trials, melanoma, PD-1, adjuvant therapy, response rate, tumor sensitivity, oncology Takeaways Resistance to immune checkpoint inhibitors is a major challenge in melanoma treatment. Primary resistance occurs when there is no benefit from treatment, while secondary resistance follows initial benefit. Defining resistance is crucial for clinical trials and understanding patient populations. The duration of drug exposure is key in determining resistance types. Clinical trial design must consider the expectations of efficacy in control arms. Investigators should be cautious about the definitions of patient populations in trials. Response rates of 15-20% are considered significant for primary resistance. Secondary resistance may show higher response rates due to residual sensitivity. Clear definitions help in layering data for future research. Collaboration among clinicians, industry, and regulatory bodies is essential for advancing cancer treatment. Sound Bites "It's probably the biggest challenge we now have in clinic." "There's something in the middle." "I think that's where we might need to be there." Chapters 00:00 Introduction to Immune Checkpoint Inhibitors and Resistance 08:08 Understanding Resistance: Definitions and Scenarios 14:47 Primary vs. Secondary Resistance in Clinical Trials 22:00 Trial Design and Control Arms in Immunotherapy 30:36 Conclusions and Future Directions 33:28 outro fade long expo.mp4

    34 min
  2. Ep 66: Ponsegromab for cancer cachexia

    MAR 30

    Ep 66: Ponsegromab for cancer cachexia

    Summary In this episode of Melanoma Matters, James Larkin and Sapna Patel discuss the recent advancements in understanding and treating cancer cachexia, particularly focusing on the drug ponsegramab. They explore the implications of cachexia across different cancer types, the role of cytokine GDF-15, and the importance of nutrition and physical activity in managing cachexia. They opine on body weight and protein, as per usual. Keywords cancer cachexia, ponsegramab, GDF-15, treatment options, nutrition, clinical trials, melanoma, kidney cancer, pancreatic cancer, weight gain Takeaways Cancer cachexia is a significant issue in various cancers. Ponsegramab shows promise in treating cachexia with meaningful weight gain. GDF15 is a key cytokine elevated in cancer cachexia. Historical treatments for cachexia have included progestins, but newer options are emerging. Nutrition and physical activity are crucial in managing cachexia. Collaboration between academia and industry is vital for drug development. The study of Ponsegramab was conducted across multiple institutions. Cachexia management requires a multifactorial approach. Clinical trials must consider the contributions of all stakeholders. Future research is needed to optimize treatment for cachexia. Sound Bites "This is about cancer cachexia." "We do see the sarcopenia." "Doctors have known about this for 2,000 years." Chapters 00:00 Introduction to Cancer Cachexia 02:43 Understanding Cachexia in Different Cancers 06:41 The Role of GDF-15 in Cancer Cachexia 10:39 Clinical Trial Insights on Ponsegramab 18:37 Exploring Treatment Implications and Future Directions 24:36 Authorship and Collaboration in Cancer Research 32:47 Fact Check 33:36 Discussion on Cancer Cachexia and Bonsegramab 38:14 Historical Context of Treatment in Kidney Cancer 42:28 Current Guidelines and Future Directions for Cachexia Treatment

    43 min
  3. Ep 65: Opdivo Qvantig (subcutaneous formulation)

    MAR 28

    Ep 65: Opdivo Qvantig (subcutaneous formulation)

    Summary In this conversation, Sapna Patel and James Larkin discuss the recent approval of Opdivo Qvantiq, a subcutaneous formulation of nivolumab, and its implications for oncology treatment. They explore the Checkmate 6-7-T study that led to its approval, the efficacy and safety of the new formulation, and the broader regulatory landscape. The discussion also touches on patient perspectives regarding subcutaneous versus intravenous treatment, the potential for future clinical trials, and the importance of patient choice in treatment options. Keywords Opdivo, Qvantiq, subcutaneous formulation, oncology, Checkmate 6-7-T, nivolumab, patient experience, regulatory approval, cancer treatment, clinical trials Takeaways The approval of Opdivo Qvantiq represents a significant advancement in oncology. Subcutaneous formulations offer convenience and the possibility of home treatment. Patient acceptance of subcutaneous treatment is generally high. The Checkmate 67T study demonstrated the efficacy of subcutaneous nivolumab. Regulatory approval for subcutaneous formulations is becoming more streamlined. Patients may value the social interaction of IV treatments over subcutaneous injections. The future of clinical trials may need to incorporate both subcutaneous and IV options. Understanding patient preferences is crucial for treatment decisions. The role of reimbursement in treatment choice cannot be overlooked. The transition from IV to subcutaneous treatment may impact patient care dynamics. Titles Revolutionizing Cancer Treatment: Opdivo Qvantiq The Future of Subcutaneous Nivolumab Sound Bites "It's a no-brainer for patients." "The FDA has taken a view there." "This is not just a flu shot." Chapters 00:00 Why does J have Napoleon on his wall? 05:36 Dreams of new work office furniture...or gym equipment 08:01 CheckMate 67T 19:31 Patient Perspectives on Subcutaneous vs. Intravenous Treatment 27:43 Regulatory and Approval Insights for Opdivo Qvantig 33:30 Future Directions in Clinical Trials 38:02 Fact Check 38:06 Subcutaneous Treatments in Oncology 41:01 Patient Experience and Acceptance of Subcutaneous Treatments 44:17 The Shift in Oncology Patient Interactions 47:06 Current Landscape of Subcutaneous Drugs in Oncology

    48 min
  4. Ep 64: Guest Clare Turnbull Part 2

    MAR 24

    Ep 64: Guest Clare Turnbull Part 2

    In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel pick up with Part 2 of 2 - a deep conversation with Claire Turnbull - about the complexities of cancer screening, overdiagnosis, and the role of genetic testing. They explore the implications of screening practices illustrated by the Gilbert Welch paradigm, the challenges faced in patient management, and the future of genetic testing in oncology. The discussion emphasizes the importance of understanding the risks and benefits associated with genetic testing. Keywords melanoma, cancer screening, overdiagnosis, genetic testing, patient management, healthcare, public health, cancer research, screening guidelines, cancer predisposition Takeaways • The conversation highlights the importance of understanding the value of cancer screening. • Overdiagnosis is a significant concern in cancer screening practices. • Genetic testing plays a crucial role in identifying cancer predisposition. • Screening should be evaluated rigorously to ensure it benefits patients. • The implications of false positives in screening can lead to unnecessary anxiety for patients. • Healthcare providers must be responsible for interpreting test results they order. • The need for genetic counseling is critical in managing test results and patient care. • There is a growing concern about the overuse of broad genetic testing panels. • Future advancements in technology may improve screening methods. • Public health messaging must address the complexities of cancer screening and genetic testing. Chapters 00:00 Clare Turnbull - Part 2 of 2 04:05 High penetrance, common SNPs, and in betweens 07:15 The Gilbert Welch Paradigm 12:30 Understanding Lead Time and Overdiagnosis 16:11 Randomized Trials in Screening 19:59 Consequences of Screening: Overdiagnosis and Anxiety 22:22 Debate on Screening Protocols and Their Efficacy 25:37 Need for Evidence-Based Genetic Testing 31:19 Ripple Effects of Genetic Testing on Families 34:00 Fact Check 35:47 Genetic testing for ACC?! 36:34 Clinical Genetics clinics are NOT just reading guidelines... 39:52 David Sackett: Evidence-Based Medicine 43:03 Triggering James: (S)he who orders the test reviews & interprets the test

    46 min
  5. Ep 63: Guest Clare Turnbull Part 1

    MAR 20

    Ep 63: Guest Clare Turnbull Part 1

    Summary In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin welcome Clare Turnbull, a clinical geneticist in London, to discuss her journey from studying mathematics to medicine, her work in cancer genetics, and the impact of COVID-19 on healthcare. The conversation explores the role of genetic testing in melanoma, the challenges of public health in cancer treatment, and the ongoing effects of the COVID-19 pandemic on cancer care and patient outcomes. Keywords melanoma, genetics, COVID-19, public health, cancer treatment, screening, early detection, healthcare, epidemiology, clinical genetics Takeaways Clare Turnbull transitioned from mathematics to medicine in uni, She has worked extensively in clinical genetics, focusing on cancer genetics. COVID-19 significantly impacted healthcare delivery and cancer treatment prioritization, the effects of which will take a long time to bear out. The importance of genetic testing in melanoma is highlighted, for young onset cases or those with a significant family history. Public health initiatives are crucial for improving cancer outcomes. The pandemic created a bulge in cancer mortality due to delayed diagnoses. Screening for melanoma is essential, but the pick-up rates for genetic mutations are low - a cautionary tale. Sound Bites "A can-do attitude, what can I do to help?" "There will be a bulge of mortality." "The pick-up rate's pretty low." Chapters 00:00 Opening theme music (My Favourite Dress...The Wedding Present) 00:48 Introduction of Guest Clare Turnbull 03:27 Clare's Journey in Clinical Genetics 05:36 Genomics England, 100K Genomes Project 06:58 Clare's extraordinary efforts during COVID 12:07 Melanoma and genetic risk(s) versus environmental risk 16:28 The Ripple Effects of Genetic Testing on Families

    29 min
  6. Ep 62: Post PD-1 studies

    MAR 18

    Ep 62: Post PD-1 studies

    Summary On mountain emergencies...Sapna's had them, James denies them...This conversation delves into the treatment options available for patients with advanced melanoma who have progressed after anti PD-1 therapy. The discussion covers various clinical studies, response rates, and the implications of combination therapy post-PD1 progression. James and Sapna conclude that while combination therapies show promise, the responses may not be as robust as those seen in frontline treatments. Keywords melanoma, PD-1, treatment, clinical trials, immunotherapy, BRAF, response rates, efficacy, combination therapy, patient outcomes Takeaways The conversation focuses on treatment options after PD-1 progression. Clinical studies provide valuable data on post-PD-1 therapies. Response rates for combination therapies are generally higher than monotherapy. BRAF status is a critical factor in treatment decisions. Randomized studies help clarify the efficacy of different treatment approaches. Combination therapy may offer better outcomes for patients post-PD-1. Acquired resistance remains a challenge. Titles Exploring Treatment Options Beyond PD-1 The Role of Clinical Trials in Melanoma Therapy Sound Bites "What to do post PD-1 exposure?" "Can you get a response to IPI after PD-1?" "The primary endpoint was PFS, not ORR... " Chapters 00:00 Opening theme music (My Favourite Dress by The Wedding Present) 01:25 Mountain rescue quickfire 03:08 Post anti-PD1 studies - the issues 04:13 Pires da Silva retrospective study 08:53 Olson single-arm prospective study (and yes we see you Jason) 10:38 SWOG S1616 randomized ph 2 study 16:35 Conclusions 17:17 Fact Check

    19 min

  7. MAR 12

    Ep 61: Guest Inge Marie Svane

    Summary In this episode of Melanoma Matters, host Sapna Patel and James Larkin welcome guest Inge Marie Svane to discuss the evolution and future of cancer immunotherapy, particularly focusing on cellular therapy for melanoma. Inge Marie shares her extensive background in the field, the establishment of a cancer immune therapy center in Denmark, and the historical context of cellular therapy. The conversation delves into the current challenges and innovations in T-cell therapy, regulatory hurdles, and the potential for cellular therapy in other solid tumors. The episode highlights the importance of optimizing treatment strategies and the need for collaboration between academia and industry and regulators to improve patient outcomes. Keywords melanoma, cancer immunotherapy, cellular therapy, T-cell therapy, checkpoint inhibitors, clinical trials, patient care, regulatory challenges, cancer vaccines, treatment advancements Takeaways Inge Marie Svane has over 25 years of experience in cancer immunotherapy.She established a center for cancer immune therapy in Denmark.T-cell therapy can benefit patients regardless of checkpoint inhibitor response.Not all patients are suitable for T-cell therapy; age and health status matter.Optimizing T-cell manufacturing processes is crucial for efficacy.Reducing side effects of T-cell therapy is a priority.Regulatory frameworks for cellular therapy are challenging in Europe.Future strategies may include genetic modifications to enhance T-cell function.Cellular therapy shows promise in other solid tumors, but challenges remain. Titles Exploring the Future of Melanoma Treatment Inge Marie Svane on Cancer Immunotherapy Innovations Sound Bites "We need to move forward in all directions." "The system is completely untrained for academia." Chapters 00:00 Introduction of Guest Inge Marie Svane 05:37 Historical Perspective on Cellular Therapy for Melanoma 09:04 Optimizing T-Cell Therapy: Challenges and Innovations 20:50 Prospects for Cellular Therapy in Other Solid Tumors

    24 min

  8. MAR 2

    Ep 60: Melanoma & Kidney Cancer w/ Mike Atkins

    Welcome to Season 2! In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin engage with Michael Atkins from Georgetown University to discuss the advancements in melanoma and kidney cancer treatments, particularly focusing on immunotherapy and cytokine treatments. They explore the groundbreaking DreamSeq trial that compares immunotherapy and targeted therapy in 1L melanoma. Keywords melanoma, immunotherapy, cytokines, DreamSeq trial, kidney cancer, cancer treatment, checkpoint inhibitors, complete response, T cells, cancer research Takeaways The introduction of checkpoint inhibitors has revolutionized cancer treatment. Cytokines like IL-2 have a historical role but are being reevaluated in modern therapy. Complete responses to therapy are crucial for durable benefits in cancer treatment. The DreamSeq trial highlights the superiority of immunotherapy over targeted therapy in certain patient populations. Understanding the tumor microenvironment is key to improving immunotherapy outcomes. The need for better imaging techniques to assess treatment responses is critical. Aggressive disease patients may require different treatment strategies than those with less aggressive disease. The importance of patient advocacy in pushing for effective cancer treatments. Future research should focus on enhancing the efficacy of immunotherapy in various cancers. Sound Bites "I love talking about melanoma and immunotherapy." "Immunotherapy was better in all the subgroups." "We need to raise the bar above nivo-IPI." Chapters 00:00 Introduction to Melanoma and Immunotherapy 10:21 The Role of Cytokines in Cancer Treatment 17:02 The DreamSeq Trial Explained 27:20 Comparing Immunotherapy and Targeted Therapy in Kidney Cancer 37:18 Final Thoughts on Immunotherapy's Future

    39 min
See All (68)

Trailer

Ratings & Reviews

5
out of 5
2 Ratings

About

From the UK to the USA - Melanoma Matters is on a mission! Hosts James Larkin and Sapna Patel are spreading the word on melanoma, one podcast at a time. Tune in for a critical review of the literature and a discussion of how we incorporate the data into our practices...across the pond(s). #MelanomaMatters video podcast

Information

  • Creator
    Melanoma Matters Pod
  • Years Active
    2024 - 2025
  • Episodes
    68
  • Rating
    Clean
  • Copyright
    © Melanoma Matters Pod
  • Show Website
    Melanoma Matters

You Might Also Like

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes, and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada